Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.0%

46 terminated/withdrawn out of 329 trials

Success Rate

84.6%

-1.9% vs industry average

Late-Stage Pipeline

37%

121 trials in Phase 3/4

Results Transparency

49%

123 of 252 completed trials have results

Key Signals

11 recruiting123 with results37 terminated9 withdrawn

Enrollment Performance

Analytics

Phase 3

92(37.9%)

Phase 2

71(29.2%)

Phase 4

29(11.9%)

N/A

28(11.5%)

Phase 1

22(9.1%)

Early Phase 1

1(0.4%)

243Total

Phase 3(92)

Phase 2(71)

Phase 4(29)

N/A(28)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (329)

Showing 20 of 329 trials

NCT06510374Phase 3Recruiting

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

Role: lead

NCT05831189Phase 3Completed

A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection

Role: lead

NCT06545955Phase 3Recruiting

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

Role: lead

NCT07263490Recruiting

PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)

Role: collaborator

NCT04113382Phase 1Recruiting

Study Assessing CLENPIQ as Bowel Preparation for Pediatric Colonoscopy

Role: lead

NCT07153367Phase 2Recruiting

Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauterine Successful Experience (RISE)

Role: collaborator

NCT06511791Phase 1Terminated

An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta at Different Time Intervals During Controlled Ovarian Stimulation.

Role: lead

NCT06466486Phase 1Terminated

An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta During Controlled Ovarian Stimulation

Role: lead

NCT07332351Phase 2Not Yet Recruiting

Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial

Role: collaborator

NCT06668493Phase 1Recruiting

Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis

Role: lead

NCT06561958Active Not Recruiting

Prospective, Multi-centre, Non-Interventional Study to Investigate the Effectiveness of REKOVELLE® for Ovarian Stimulation for Asian Women in Real World Settings

Role: lead

NCT06026332Terminated

ADSTILADRIN Early Utilization and Outcomes in the Real World Setting

Role: lead

NCT06173869Phase 3Completed

A Randomised Trial Comparing the Ovarian Response of a Starting Dose of Either 10 μg or 15 μg Follitropin Delta (FE 999049) to a Starting Dose of Either 150 IU or 225 IU Follitropin Alfa (GONAL-F) in Conventional Regimens in China

Role: lead

NCT05835219Completed

REBYOTA™ Prospective Registry

Role: lead

NCT07154888Not ApplicableActive Not Recruiting

Fast Track to Fertility

Role: collaborator

NCT07029451Recruiting

To Investigate REKOVELLE in Chinese Women Undergoing Assisted Reproductive Technologies: Effectiveness, Safety, and Patterns of Use in Real-world Practice

Role: lead

NCT00117286Phase 2Completed

Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer

Role: lead

NCT05555121Phase 2Suspended

Rescue Progesterone Supplementation During Frozen Embryo Transfer

Role: collaborator

NCT04740645Completed

NOCDURNA PASS Study Using Registries in Denmark, Germany and Sweden

Role: lead

NCT07152730Phase 1Withdrawn

A Study to Measure Pharmacokinetic (PK) Concentrations of Gonadotropin-Releasing Hormone Delivered by the OmniPod Pump

Role: lead